Health Care • Pharmaceuticals and Biotechnology
$7.25 ▼ -0.13
(-1.76%)
MKT CAP: $477.8M • VOL: 1.02M
52W L $5 52W H $9
ROARABLE / RQD
D- • 36/100
PIOTROSKI
2 / 9
EPRX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $0 | $0 | $0 |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$38.6M | -$25.5M | -$28.2M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$28.6M | -$30.0M | -$20.7M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$28.6M | -$30.0M | -$20.7M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | — | — | — |
| Cash & Short-Term Equivalents | $80.6M | $33.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $82.0M | $33.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR EPRX.